Clinical trials: Myosteatosis
Cirrhosis, Myosteatosis
Protocol for Muscle Attenuation Cut-offs in Cirrhosis
The goal of this observational study is to learn if new muscle attenuation cut-offs for the definition of myosteatosis can better predict survival in patients with cirrhosis.
- Conditions
- Cirrhosis, Myosteatosis, Sarcopenia, Sarcopenia in Liver Cirrhosis
- Trial name
- Myocirrhosis (NCT06593015)
- Testing
- Radiological tool for the diagnosis of myosteatosis
- Where
- Italy
- Volunteers
- 1,296 people
- Sponsor
- University of Roma La Sapienza
Retroperitoneal Sarcoma, Body Composition
Influence of Nutritional Status on Oncologic and Operative Outcome in Patients Operated for Retroperitoneal Sarcoma
This is a retrospective, observational study in consecutive patients operated on for primary RPS in the Institute of Oncology Ljubljana (Slovenia) between September 1999 and June 2020.
- Conditions
- Retroperitoneal Sarcoma, Body Composition, Malnutrition, Sarcopenia
- Trial name
- NCT05631379
- Testing
- Measurement of body composition with computed tomography (CT), GLIM malnutrition criteria, EWGSOP2 sarcopenia criteria
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- Institute of Oncology Ljubljana
Cushing Syndrome, Acromegaly
Muscle in Acromegaly and Cushing's Syndrome
Cushing's syndrome (CS) and acromegaly determine myopathy and muscle weakness which persist long-term after control of hormone excess.
- Trial name
- MAC (NCT03673761)
- Testing
- MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Skeletal Muscle Radiodensity, Myosteatosis
Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a 5-year survival rate as low as 6%. It causes body composition changes and many patients develop muscle loss with disease progression.
- Conditions
- Skeletal Muscle Radiodensity, Myosteatosis, Scr/CysC Ratio, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05584852
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Cirrhosis
A Cross Sectional Study for Determining Prevalence of Sarcopenia and Myosteatosis in Cirrhotic Patients and to Study the Association Between Imaging and Clinical Parameters
Cirrhosis is associated with a wide variety of metabolic changes in the body. Ascites, hepatic encephalopathy, variceal bleeding, renal dysfunction, and hepatocellular carcinoma are the most widely recognised complications in…
- Trial name
- Myo (NCT05157308)
- Where
- India
- Volunteers
- 385 people
- Sponsor
- Asian Institute of Gastroenterology, India
Sarcopenia, Body Composition
CT Body Composition as Predictor of Exercise Therapy Outcome in Peripheral Arterial Disease
Supervised exercise therapy (SET) is the recommended first treatment for patients with leg artery disease (peripheral arterial disease, PAD) causing pain when walking.
- Conditions
- Sarcopenia, Body Composition, Sarcopenic Obesity, Peripheral Arterial Disease
- Trial name
- COMPOSE-PAD (NCT07433309)
- Testing
- SET physiotherapy, CT scan
- Volunteers
- 128 people
- Sponsor
- Nemocnice AGEL Trinec-Podlesi a.s.
Sarcopenia
Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans
The objectives of this study are to: 1) validate a rapid, portable, cost-effective method for screening myosteatosis and sarcopenia using diagnostic ultrasound, and 2) investigate a novel approach to progressive resistance…
- Trial name
- ARMS-II (NCT02350465)
- Testing
- Eccentric Exercise, Concentric Exercise
- Where
- 3 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cirrhosis, Portal Hypertension
Evaluation of Minimal Hepatic Encephalopathy in Patients With Cirrhosis and Portal Hypertension
Minimal hepatic encephalopathy (MHE) is a subclinical cognitive impairment and represents the mildest type of hepatic encephalopathy (HE).
- Trial name
- Evencipor (NCT04807803)
- Testing
- Assessment of Minimal hepatic encephalopathy (MHE)
- Where
- 2 sites in France
- Volunteers
- 82 people
- Sponsor
- IHU Strasbourg
Sarcopenia, Colonic Neoplasms
ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes
So far, the impact of sarcopenia has been analysed only in patients undergoing traditional surgical procedures (laparotomy) or those with metastatic spread.
- Trial name
- NCT02618811
- Where
- Poland
- Volunteers
- 171 people
- Sponsor
- Jagiellonian University
Metabolic Dysfunction-associated Steatotic Liver Disease
Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity.
- Trial name
- MYO-MASLD (NCT06506513)
- Testing
- High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training
- Where
- 2 sites in Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Bladder Cancer Cell Transitional
Sarcopenia and NMIBC Prognosis Study
The goal of this observational study is to evaluate whether body composition abnormalities (sarcopenia, myosteatosis, and obesity) and nutritional status influence the risk of recurrence and progression in adult patients with…
- Trial name
- SARC-NMIBC (NCT07285408)
- Volunteers
- 150 people
- Sponsor
- General Hospital Sveti Duh
Chronic Kidney Disease(CKD), Myosteatosis
The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD
Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals.
- Conditions
- Chronic Kidney Disease(CKD), Myosteatosis, Mitochondrial Dysfunction, Muscle Function
- Trial name
- EPIC-CKD (NCT06631820)
- Testing
- Epicatechin extract
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska Institutet
Sarcopenia, Sarcopenic Obesity
The Relationship Betweensarcopenia And Myosteatosis With The Natural History Of Liver Cirrhosis
Malnutrition is a common figure associated with liver cirrhosis. The main component of malnutrition in liver cirrhosis is represented by sarcopenia, a condition of a progressive and generalized loss of muscle mass and strength.
- Conditions
- Sarcopenia, Sarcopenic Obesity, Cirrhosis, Liver
- Trial name
- NCT04466709
- Testing
- none intervention type
- Where
- Italy
- Volunteers
- 374 people
- Sponsor
- University of Roma La Sapienza
Frail Elderly Syndrome, Diabetes
Muscle Multi-parametric NMR Imaging Development in Aged People With Sarcopenia or Frailty Syndrome; CLINical Study
Frailty is a multideterminant syndrome in which muscle function appears to play a central role. Muscle function depends on brain control, nutrition and perfusion.
- Trial name
- MIDAS (NCT04238494)
- Testing
- Nuclear magnetic resonance (NMR)
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Cirrhosis, Liver, Sarcopenia
Building of Prognosis Model for Patients With Cirrhosis Based on Sarcopenia Assessed by Deep Learning
The goal of this observational study is to develop and validate a fully automated imaging deep learning platform for the evaluation of sarcopenia in liver cirrhosis.
- Trial name
- NCT06531200
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease
Investigating Myosteatosis in Steatotic Liver Diseases
Steatotic liver diseases (SLD) are the most common chronic liver diseases worldwide. SLD are defined by an excessive liver lipid content (steatosis) of more than 5% of the total liver weight and includes 3 clinical entities …
- Conditions
- Alcohol-related Liver Disease, Metabolic Dysfunction Associated Steatotic Liver Disease, Steatotic Liver Disease of Mixed Origin (MetALD), Steatotic Liver Diseases
- Trial name
- MYO-SLD (NCT06514300)
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Endovascular Aneurysm Repair (EVAR)
Evaluating the Impact of Psoas Muscle Size, Composition, and Clinical Frailty on Long-term Outcomes Following Elective Endovascular Aneurysm Repair
Sarcopenia, which is characterized by the progressive loss of skeletal muscle mass and strength, has emerged as a significant prognostic biomarker in the field of vascular surgery, particularly regarding endovascular aneurysm…
- Trial name
- NCT06864247
- Testing
- No Intervention: Observational Cohort
- Where
- Taiwan
- Volunteers
- 525 people
- Sponsor
- National Taiwan University Hospital
Sarcopenia, Connective Tissue Diseases in Old Age
RCT of Combination Effect of Vibration Treatment and HMB Supplementation on Myosteatosis and NMJ Degeneration
The investigators' pre-clinical study confirms the positive effects of combined treatment (VT + HMB) on reducing fat-to-lean tissue ratio, intramuscular fat infiltration and increasing muscle strength in sarcopenia animal model.
- Conditions
- Sarcopenia, Connective Tissue Diseases in Old Age, Musculoskeletal Abnormalities
- Trial name
- NCT05525039
- Testing
- Low-magnitude High-frequency Vibration, β-hydroxy β-methylbutyrate (HMB) supplement, Protein supplement
- Where
- 3 sites in Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Cancer, Gastric Cancer
Myosteatosis in Oeso-gastric Cancer: Clinical Impacts
The aim of this project is to study the presence of cancer-associated adipocytes in oesogastric cancers and their possible links with myosteatosis.
- Conditions
- Esophageal Cancer, Gastric Cancer, Myopenia, Adipose Tissue Tumor
- Trial name
- NCT06419244
- Testing
- Myosteatosis
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Obesity (Disorder)
Tirzepatide and Muscle Outcomes in Obesity
This study is evaluating whether a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, can affect the function, structure and metabolism of skeletal muscles…
- Trial name
- TIRMO (NCT07373834)
- Testing
- Tirzepatide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana